DK3253762T3 - 9h-pyrrolo-dipyridinderivater. - Google Patents

9h-pyrrolo-dipyridinderivater. Download PDF

Info

Publication number
DK3253762T3
DK3253762T3 DK16702121.1T DK16702121T DK3253762T3 DK 3253762 T3 DK3253762 T3 DK 3253762T3 DK 16702121 T DK16702121 T DK 16702121T DK 3253762 T3 DK3253762 T3 DK 3253762T3
Authority
DK
Denmark
Prior art keywords
pyrrolo
dipyridine
derivatives
dipyridine derivatives
Prior art date
Application number
DK16702121.1T
Other languages
Danish (da)
English (en)
Inventor
Joël Mercier
Laurent Provins
Celine Vermeiren
Yogesh Anil Sabnis
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Application granted granted Critical
Publication of DK3253762T3 publication Critical patent/DK3253762T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK16702121.1T 2015-02-02 2016-01-29 9h-pyrrolo-dipyridinderivater. DK3253762T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15153448 2015-02-02
PCT/EP2016/051993 WO2016124508A1 (en) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridine derivatives

Publications (1)

Publication Number Publication Date
DK3253762T3 true DK3253762T3 (da) 2021-07-19

Family

ID=52477553

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16702121.1T DK3253762T3 (da) 2015-02-02 2016-01-29 9h-pyrrolo-dipyridinderivater.

Country Status (17)

Country Link
US (3) US20180022748A1 (enExample)
EP (1) EP3253762B1 (enExample)
JP (1) JP6579670B2 (enExample)
KR (1) KR102621513B1 (enExample)
CN (1) CN107207508B (enExample)
AU (1) AU2016214537B2 (enExample)
BR (1) BR112017016311A2 (enExample)
CA (1) CA2973648C (enExample)
CL (1) CL2017001923A1 (enExample)
DK (1) DK3253762T3 (enExample)
EA (1) EA036518B1 (enExample)
ES (1) ES2875734T3 (enExample)
IL (1) IL253381B (enExample)
MX (1) MX378155B (enExample)
MY (1) MY191590A (enExample)
SG (1) SG11201705727TA (enExample)
WO (1) WO2016124508A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2247558B2 (en) 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
EA036518B1 (ru) * 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина
KR102472003B1 (ko) * 2016-07-22 2022-11-29 에이씨 이뮨 에스에이 타우 단백질 응집체를 이미징하기 위한 화합물
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
MX375720B (es) * 2016-09-09 2025-03-04 Hoffmann La Roche Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol.
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
CA3067455C (en) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
JP7370859B2 (ja) * 2017-06-02 2023-10-30 富士フイルム富山化学株式会社 タウオパチー予防または治療剤
KR20190137936A (ko) 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
MX393006B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
JP7227914B2 (ja) 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
US20210041447A1 (en) * 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
SG11202006543QA (en) * 2018-01-24 2020-08-28 Ac Immune Sa Novel method of preparing an imaging compound
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1268771A (en) 1968-03-15 1972-03-29 Glaxo Lab Ltd Azacarbazoles
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
EP2247558B2 (en) * 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
EP2370407B1 (en) * 2008-12-19 2014-06-18 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
CN104781234A (zh) 2012-05-22 2015-07-15 伊莱利利公司 用于检测神经功能障碍的基于咔啉和咔唑的成像剂
US20160115162A1 (en) * 2013-05-31 2016-04-28 The General Hospital Corporation Radiosynthesis of Tau Radiopharmaceuticals
CN105379130B (zh) * 2013-07-24 2017-08-22 瑞典爱立信有限公司 与无线电信号的接收有关的方法和设备
CN105358558B (zh) * 2013-10-08 2017-09-26 豪夫迈·罗氏有限公司 作为tau‑pet‑配体的二氮杂咔唑衍生物
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
EA036518B1 (ru) * 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина

Also Published As

Publication number Publication date
US20220213103A1 (en) 2022-07-07
US12006316B2 (en) 2024-06-11
EP3253762A1 (en) 2017-12-13
KR102621513B1 (ko) 2024-01-04
US11312716B2 (en) 2022-04-26
CA2973648A1 (en) 2016-08-11
CN107207508B (zh) 2020-02-28
SG11201705727TA (en) 2017-08-30
IL253381A0 (en) 2017-09-28
JP6579670B2 (ja) 2019-09-25
EA201791733A1 (ru) 2018-01-31
EA036518B1 (ru) 2020-11-18
US20180022748A1 (en) 2018-01-25
BR112017016311A2 (pt) 2018-03-27
WO2016124508A1 (en) 2016-08-11
KR20170113607A (ko) 2017-10-12
JP2018503673A (ja) 2018-02-08
US20210047326A1 (en) 2021-02-18
MX378155B (es) 2025-03-10
AU2016214537A1 (en) 2017-08-03
CL2017001923A1 (es) 2018-02-16
MX2017009505A (es) 2017-11-02
IL253381B (en) 2020-10-29
ES2875734T3 (es) 2021-11-11
AU2016214537B2 (en) 2018-05-10
CA2973648C (en) 2023-09-26
MY191590A (en) 2022-06-30
CN107207508A (zh) 2017-09-26
EP3253762B1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
DK3319956T3 (da) Substituerede oxopyridinderivater
PL3345230T3 (pl) Podwójny perowskit
DK3283625T3 (da) Nukleasemedieret genomeditering
DK3331869T3 (da) Muscarinagonister
LT3230281T (lt) 1,3-tiazol-2-ilu pakeisti benzamidai
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3360890T3 (da) Genterapi
DK3305788T3 (da) Janus-kinase-hæmmer
DK3331529T3 (da) Muskarinagonister
EP3713931C0 (en) 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDE
DK3310450T3 (da) Olie-vand-separator
LT3402792T (lt) Chinolin-2-ono dariniai
LT3457851T (lt) Sobetiromo dariniai
DK3270930T3 (da) Præeklampsi
BR112017001387A2 (pt) alargador.
FR3023988B3 (fr) .
LT3371168T (lt) Indolin-2-ono dariniai
BR112017001389A2 (pt) alargador.
BR112017001386A2 (pt) alargador.
BR112017001388A2 (pt) alargador.
IT201600084952A1 (it) Coglifrutta.
ES1150114Y (es) Abarcón.
DK3292136T3 (da) Penicillin-g-acylaser